Lacramioara Ivanciu, PhD
Research Assistant Professor of Pediatrics (Hematology)
Member, Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia
Member, Blood Center for Patient Care and Discovery, Children's Hospital of Philadelphia and University of Pennsylvania
Member, Cardiovascular Institute, University of Pennsylvania School of Medicine
Department: Pediatrics
Contact information
Children's Hospital of Philadelphia
3501 Civic Center Blvd.
Philadelphia, PA 19104
3501 Civic Center Blvd.
Philadelphia, PA 19104
Office: 267-426-7431
Fax: 215-590-3660
Fax: 215-590-3660
Email:
ivanciul@chop.edu
ivanciul@chop.edu
Education:
B.A.
University of Bucharest, Romania (Biology), 1995.
M.S.
University of Bucharest, Romania (Biology), 1996.
Ph.D.
University of Bucharest, Romania (Biology), 2004.
Permanent linkB.A.
University of Bucharest, Romania (Biology), 1995.
M.S.
University of Bucharest, Romania (Biology), 1996.
Ph.D.
University of Bucharest, Romania (Biology), 2004.
Selected Publications
Poncz M, Zaitsev S, Ahn H, Kowalska MA, Bdeir K, Vladimirovich K, Ivanciu L, Camire RM, Cines DB, Stepanova V.: Packaging of supplemental urokinase into alpha-granules of the in vitro-grown megakaryocytic for targeted nascent clot lysis. Blood Advances 8(14): 3798-3809, Jul 2024.Ivanciu L, Bos MHA, Camire RM: Enhanced activation of FVIII positively impacts clot formation in vivo using hemophilia A mice. Thrombosis & Hemostasis Summit of North America, Chicago, IL, Oral presentation Apr 2024.
Quin SM, Ivanciu L, Aymobil F, and Camire RM: A monoclonal antibody targeting human FV enhances thrombin generation and reduces bleeding in hemophilia A mouse model Annual Bleeding Disorders Conference, National Harbor, MD, Poster presentation Aug 2023.
Ivanciu L: Optimization of a tail vein transection bleeding model in hemophilia A. Journal of Thrombosis and Haemostasis 21(5): 1107-1108, May 2023.
Ivanciu L, Arruda V, and Camire RM: Factor IXa variants resistant to plasma inhibitors enhance clot formation in vivo. Blood 141(16): 2022-2032, Apr 2023.
Gordon D: NHF Fellowship: 50 Years of Insights, Innovation, and Breakthroughs. HemAware Dec 2022 Notes: Ivanciu L. interviewed.
Quin S, Ivanciu L, Davidson RJ, Ayombil F, and Camire RM: An antibody targeting human FV promotes thrombin generation and reduces bleeding in a hemophilic mouse model 64th American Society of Hematology Annual Meeting, New Orleans, LA, Oral presentation Dec 2022.
Quinn S, Ivanciu L, Davidson RJ, Ayombil F, Crosby JR, Revenko AS, Macleod AR, Monia BP, and Camire RM: Antibody GB5 targets human FV to enhance its activity and reduce bleeding in the context of hemophilia Gordon Research Conference on Hemostasis, Waterville Valley, NH, Poster presentation Aug 2022.
Quinn S, Ivanciu L, Davidson R, Ayombil F, Crosby JR, Revenko AS, Macleod RA, Monia Br, and Camire RM. : Protection of human Factor V from Activated Protein C using a monoclonal antibody - biochemical characterization and evaluation using a mouse injury model. 63rd American Society of Hematology Annual Meeting, Atlanta, GA, Poster presentation Dec 2021.
Quinn S, Ivanciu L, Davidson R, Ayombil F, Crosby JR, Revenko AS, Macleod RA, Monia Br, and Camire RM : Discovery of a human FV antibody (GB5) which enhances thrombus formation and promotes thrombin generation in the presence of APC. 50th Annual Philadelphia Workshop on Hemostasis, Thrombosis and Atherosclerosis, Jefferson University, Philadelphia, PA, Oral presentation Nov 2021.